November 5 th, 2013 FOCUS 2014 COMPETITION

Transcription

1 November 5 th, 2013 FOCUS 2014 COMPETITION

2 A COLLABORATIVE APPROACH TO FOSTER BIOPHARMACEUTICAL R&D Vision To be a global leader actively involved in creating Canadian and International networks dedicated to the advancement of nextgeneration technologies with the ultimate goal of bringing better cures to patients Mission To identify, fund and support breakthrough technologies that will significantly enhance biopharmaceutical R&D productivity and accelerate the development of new safe and efficacious drugs To establish a neutral ground that brings patients groups, academia, governments, biotech and the pharma industry together to work collaboratively on complex medical challenges

3 OUR FUNDING PROGRAMS EXPLORE Unconventional highly innovative ideas disruptive technologies FOCUS Innovative technologies immediate impact on drug discovery/development Development projects QUEBEC/FRANCE Collaborative projects between Quebec, Alsace and/or Rhône-Alpes QUEBEC/ONTARIO Collaborative projects between Quebec and Ontario Development projects Early concept validation Multi-institutional/ multidisciplinary teams Development projects Multi-institutional/ multidisciplinary teams Single or multiple labs Public/private partnership not required Maximum $300K over 2 years Public/private partnership encouraged Maximum $2M over 3 years Multi-institutional/ multidisciplinary teams At least 1 research entity from Quebec and 1 from Alsace or Rhône-Alpes Maximum $700K (Qc)/500K (Fr) over 3 years At least 1 research entity from Quebec and 1 from Ontario Maximum $750K $375K (Qc) from CQDM $375K (On) from other sources

4 A STRONG IMPACT ON THE DEVELOPMENT OF NEW DRUGS 5 YEARS - $29.4 M Shore Synthetic lethality oncology Chelsky/Gasman Drug targets neuroendocrine tumours Blais-Ouellette/Bischoff Protein-protein interactions CNS target discovery Richards Somatic mutations of reacting T cells inflammatory diseases Bouvier Biosensors GPCR signalling Vezina Discovery platform VLP vaccine Ag Yudin/Marsault Macrocycles library Protein-protein interactions Pineyro Biosensors for ion channels Götte Screening methods antivirals Bouvier/Kieffer New engineered mice for GPCR studies Hébert Dynamic response to GPCR drugs Najmanovich Molecular interactions field platform Purisima In silico predictivity of mab affinity Mes-Masson Microfluidic platform for cancer therapy Escher Real-time in vivo analyte measurement ADME studies Bergeron Resistance to antibiotics Mishra/DiPaolo Parkinson s disease Early diagnosis and treatment Bedell Animal models Alzheimer s disease Paramithiotis Early diagnostics diabetes Hoge Patient stratification Alzheimer s disease Maziade ERG biomarkers psychiatric disorders Martel Magnetic guided drug delivery platform Dupuis Imaging biomarker pulmonary hypertension Park Stromal biomarkers breast cancer Kremer Method to isolate circulating cancer cells

5 SCOPE OF THE PROGRAM To promote the development of novel and innovative technologies that address current and critical challenges faced by the pharmaceutical industry To develop cutting-edge next-generation technologies with an immediate and strong impact on the discovery/development of new drugs Not intended to fund the development of specific molecules

6 ELIGIBILITY Research performed in the province of Québec Academic laboratories, affiliated research institutes, hospitals, SMEs, biotechs, CROs Public/private partnerships prioritized Address most important challenges of the biopharmaceutical industry Generate clear deliverables with immediate applications in the drug R&D process Multinational pharmaceutical companies not eligible

7 RESEARCH AGENDA Broad research agenda All therapeutic indications: cardiology, infectious diseases, inflammatory diseases, metabolic diseases, neurosciences, oncology, etc. All research fields/disciplines: biological and health sciences, chemistry, engineering, nanotechnologies, computational sciences, medical devices, imaging, biosensors, in silico and in vitro screening systems, and improved disease-relevant animal models, etc. Well-defined near-term application with potential to significantly impact biopharmaceutical R&D

8 CQDM FUNDING SPECIFICS Duration: Maximum 3 years Total amount: Maximum 2M$ Eligible costs: Salary of research personnel; Material and supplies; Travel expenses; Intellectual property costs; Administrative costs (up to 15%) Non-eligible costs: Equipment or facilities; Salary of the principal investigator and co-investigators

9 EVALUATION AND FUNDING PROCESS Advisory Board Research Entities LOIs Full applications Final selection Research agreements Beginning of the projects External Review Committee CQDM risk analysis CA Advisory Board CQDM

10 EVALUATION CRITERIA Scientific excellence Creativity and innovation Competitiveness in the scientific field of the proposal Feasibility to execute project within time and budget Clear and well-defined milestones and deliverables Potential of applications in drug research o o immediate impact on drug discovery or drug development capacity to address important unmet needs Track record of the participants Multidisciplinary and multi-organizational aspects of the research Complementarity between partners

11 POSITIONING/COMPETITIVENESS Not about the team or facilities It s all about the technology, product, tool, device Identify: Current state of the art Competition: o Direct and indirect o Local and international o Existing or in development Compare your technology, product, tool, device Bring out: Advantages Differentiating factors Originality and novelty aspects

12 MONITORING OF FUNDED PROJECTS For all funded projects: Project managers must be identified Contact person and coordination of reports Disbursements subject to milestones achievement and satisfactory follow-ups Quarterly financial report Semi-annual scientific progress report

13 PHARMA MENTORS PROVIDE INVALUABLE SUPPORT Minimally one pharma mentor Opportunity for researchers to create strong links and collaborate with pharma industry Two meetings/year (co-ordinated by CQDM) Informal interactions throughout year Mentors role? Ensure technology developed fully aligned with industry needs Eager to aid with project success in mind (not to evaluate) May provide additional resources (clinical samples, database, specific expertise)... mutual benefits for researchers and CQDM pharma members

14 TIMETABLE FOCUS 2014 COMPETITION Important dates Program launch October 3 rd, 2013 Deadline for submission of the letters of intent November 14 th, 2013 Announcement of the selected letters of intent December 19 th, 2013 Deadline to submit full proposals March 13 th, 2014 Final selection announcement July 24 th, 2014 Signature of a research agreement November 27 th, 2014 Funding release and beginning of the projects December 2 nd, 2014

15 CQDM LICENSING POLICY Owned by researchers and research entities Background IP Project Results Deliverables New IP Know how Data Copyrights No new IP R&D Use Commercialization CQDM Pharma sponsors

16 EXAMPLES OF DELIVERABLES Software for data analysis or data measurement Validated biomarkers Diagnostic tools Imaging tools New processes Medical devices or instruments Prototypes Molecular signatures Validated therapeutic targets Delivery systems Predictive algorithms Etc...

17 EXAMPLES OF FUNDED PROJECTS Biomarkers in diabetes (E. Paramithiotis, Caprion Proteomics) Early diagnosis Better monitoring of the progression of the disease Evaluation of response to treatments Biosensors to dissect GPCR induced signalling pathways (M. Bouvier, IRIC) Monitoring of multiple signalling pathways Signalling signature for the prediction of activity and side effects of new drugs Discovery platform for new vaccine VLP antigens (L. Vézina, Medicago) Generic high-throughput expression & purification platform for VLP antigens Rapid identification of immunogenic VLP vaccine candidates among several classes of viruses Screening Assay for Antivirals (M. Götte, McGill) Highly sensitive technology based on phages to reduce time and costs associated with screening of antiherpetic compounds

18 EXAMPLES OF FUNDED PROJECTS Profiling Psychiatric Disorders (M. Maziade, U. Laval) Use of ERG to stratify patients with psychiatric disorders and to measure the pharmacological response to treatments Drug Delivery Platform for the Treatment of Colorectal Cancer (S. Martel, École polytechnique de Montréal) Use of magnetotactic bacteria to deliver anti cancer drug at the tumor site Imaging Method for Pulmonary Hypertension (J. Dupuis, MHI) Detection of early abnormalities of the lung blood circulation Early/effective diagnosis of pulmonary hypertension Evaluation of the disease progression Quantitative O2 MRI for Alzheimer's Disease (R. Hoge, Institut universitaire de gériatrie de Montréal) Non-invasive imaging of oxidative metabolism in the brain Identification of new mechanisms of action for AD drugs Improving patient selection in clinical trials Providing new therapeutic endpoints for assessment of drug efficacy

19 CQDM CONTACT INFORMATION Judith Caron, Ph.D., MBA Director of Programs Helen Loughrey, Ph.D. Senior Director, Scientific Affairs More information: Phone: (514) Merci de votre attention! Thank you for your participation!